47.69
Precedente Chiudi:
$48.68
Aprire:
$48.44
Volume 24 ore:
1.04M
Relative Volume:
0.70
Capitalizzazione di mercato:
$3.39B
Reddito:
-
Utile/perdita netta:
$-218.28M
Rapporto P/E:
-13.32
EPS:
-3.5803
Flusso di cassa netto:
$-186.55M
1 W Prestazione:
-5.83%
1M Prestazione:
+5.91%
6M Prestazione:
+107.35%
1 anno Prestazione:
+13.04%
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
VERA
Vera Therapeutics Inc
|
47.69 | 3.46B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Is Vera Therapeutics Inc. stock gaining market shareJuly 2025 Intraday Action & Stepwise Trade Execution Plans - ulpravda.ru
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Shift From Loss To Profit - 富途牛牛
Will Vera Therapeutics Inc. stock attract ESG investorsRisk Management & AI Powered Market Entry Ideas - ulpravda.ru
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ - openPR.com
Why Vera Therapeutics Stock Zoomed Higher Today - The Globe and Mail
FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review - Investing.com Nigeria
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review By Investing.com - Investing.com South Africa
Vera Therapeutics shares up 3% after co receives U.S. FDA priority review for kidney disease drug - MarketScreener
Vera Therapeutics' Atacicept Receives FDA Priority Review for Treatment of IgAN with PDUFA Date Set for July 7, 2026 - Quiver Quantitative
New weekly shot for serious kidney disease gets priority FDA review - Stock Titan
FDA Expedites Approval of Vera’s Home-Based Kidney Medication - Bitget
Wells Fargo sees short squeeze ahead: here are three stocks to play it - TradingView — Track All Markets
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Vera Therapeutics Earnings Notes - Trefis
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
450,700 Shares in Vera Therapeutics, Inc. $VERA Acquired by Capricorn Fund Managers Ltd - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - ts2.tech
Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year HighShould You Buy? - MarketBeat
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects - Sahm
Vera Therapeutics Appoints James R. Meyers to Board - MSN
Vera’s New Capital Raise and Legal Transition Might Change The Case For Investing In Vera Therapeutics (VERA) - Sahm
How risky is Vera Therapeutics Inc. stock now2025 Market Overview & Smart Swing Trading Alerts - Улправда
Weekly Earnings: How Vera Therapeutics Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Momentum Based Trading Ideas - ulpravda.ru
Recap Report: Will Vera Therapeutics Inc. stock attract ESG investorsLong Setup & Long-Term Safe Investment Plans - moha.gov.vn
Vera Therapeutics, Inc. $VERA Shares Acquired by Squarepoint Ops LLC - MarketBeat
Goldman Sachs Maintains Vera Therapeutics (VERA) Buy Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 51.23 USD By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Vera Therapeutics Investors Drop Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics stock hits 52-week high at 51.23 USD - Investing.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Given New $96.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Is Vera Therapeutics Inc. stock oversold or undervalued2025 Market Trends & Fast Gain Swing Alerts - Улправда
Goldman Sachs raises Vera Therapeutics stock price target to $95 on IgAN pricing - Investing.com Canada
Vera Therapeutics stock price target raised to $66 by BofA Securities - Investing.com Canada
Will Vera Therapeutics Inc. stock maintain growth storyIndex Update & Weekly Breakout Watchlists - DonanımHaber
What risks investors should watch in Vera Therapeutics Inc. stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - DonanımHaber
How Vera Therapeutics Inc. stock valuations compare to rivalsEarnings Recap Report & Low Volatility Stock Recommendations - Улправда
Aug Closing: How Vera Therapeutics Inc. stock valuations compare to rivalsShare Buyback & Daily Technical Forecast Reports - Улправда
Vera Therapeutics Announces Departure of Chief Legal Officer - TipRanks
Vera Therapeutics, Inc. Announces Departure of Jason Carter as Chief Legal Officer, Effective December 24, 2025 - marketscreener.com
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):